Celldex Therapeutics (CLDX) Payables (2010 - 2026)

Celldex Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• In Q1 2026, Payables rose 203.78% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (up 203.78% YoY), while the FY2025 annual figure was $1.2 million, down 63.86% from the prior year.
• Payables for Q1 2026 stood at $10.4 million, up from $1.2 million in the prior quarter.
• The five-year high for Payables was $10.4 million in Q1 2026, with the low at $881000.0 in Q2 2023.
• The 5-year median for Payables is $3.3 million (2024), against an average of $3.0 million.
• Peak annual rise in Payables reached 331.56% in 2024, while the deepest fall reached 68.93% in 2024.
• Celldex Therapeutics' Payables stood at $3.3 million in 2022, then gained by 4.61% to $3.5 million in 2023, then fell by 6.55% to $3.3 million in 2024, then tumbled by 63.86% to $1.2 million in 2025, then jumped by 777.88% to $10.4 million in 2026.
• Business Quant data shows CLDX's Payables at $10.4 million in Q1 2026, $1.2 million in Q4 2025, and $4.3 million in Q3 2025.